What is Cormark's Estimate for Curaleaf FY2024 Earnings?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Equities researchers at Cormark lowered their FY2024 earnings per share (EPS) estimates for Curaleaf in a research report issued on Thursday, November 7th. Cormark analyst J. Pytlak now anticipates that the company will post earnings per share of ($0.27) for the year, down from their prior forecast of ($0.25). Cormark currently has a "Hold" rating on the stock. The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Cormark also issued estimates for Curaleaf's FY2025 earnings at ($0.19) EPS.

Separately, Needham & Company LLC reissued a "buy" rating and set a $6.25 target price on shares of Curaleaf in a research report on Thursday, August 8th.

Curaleaf Trading Down 22.1 %

Curaleaf stock traded down $0.47 during trading on Monday, hitting $1.66. The company's stock had a trading volume of 3,126,765 shares, compared to its average volume of 702,513. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.50 and a current ratio of 1.09. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -5.72 and a beta of 0.86. The stock's fifty day moving average is $2.95 and its 200 day moving average is $3.77. Curaleaf has a 1-year low of $1.64 and a 1-year high of $6.40.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.